In contrast with the administration of anti-FGF23 antibodies in younger mice, and despite the full correction of hypophosphatemia, 12-week-old Dmp1-null mice showed only a partial rescue of bone growth and mineralization. Here, FGF23 is linked to hypophosphatemia.